Abstracts tagged "Prognosis"

Abstract Number: 0863 • ACR Convergence 2021
Serum Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Cardiovascular Risk in Systemic Lupus Erythematosus: A Longitudinal Cohort Study
Chi Chiu Mok¹, Ling Yin Ho², Kar Li Chan³, Sau Mei TSE² and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Tuen Mun Hospital, Hong Kong, ⁴Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the predictive value of serum PCSK9 level on cardiovascular complications in Chinese patients with systemic lupus erythematosus (SLE).Methods: Consecutive patients who fulfilled…
Abstract Number: 1040 • ACR Convergence 2021
Monoclonal Gammopathy in Autoimmune Diseases: Analysis and Follow-up of 160 Cases in a Tertiary Center in China
Huazhen Liu, Pengchong Li, Ketian Li, Ziyue Zhou, Lidan Zhao and Xuan Zhang, Peking Union Medical College Hospital, Beijing, China (People's Republic)
Background/Purpose: Monoclonal gammopathy (MG) in patients with autoimmune diseases (AID) is pretty common, but the outcomes and predictors for hematological neoplasm (HN) progression have not…
Abstract Number: 465 • 2019 ACR/ARP Annual Meeting
Prognostic Factors and Clinical Outcome Modifiers in Patients with Rheumatoid Arthritis: A Review
Leticia Ferri¹, Grace Crocket ², Xue Han ¹, Boris Breznen ³ and Mir Sohail Fazeli ³, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²Bristol-Myers Squibb; Rutgers University, New York City, NY, ³Doctor Evidence, Santa Monica, CA
Background/Purpose: The current goal in treatment of RA is to deliver therapies tailored to individual patients’ characteristics. Establishing disease prognosis is a crucial first step…
Abstract Number: 2349 • 2019 ACR/ARP Annual Meeting
Epidemiology, Risk/Prognostic Factors, and Treatment Landscape in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Literature Review
Xue Han¹, Leticia Ferri ¹, Grace Crocket ², Sophie Yoon ³, Tracy Slanger ³ and Mir Sohail Fazeli ³, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²Bristol-Myers Squibb; Rutgers University, New York City, NY, ³Doctor Evidence, Santa Monica, CA
Background/Purpose: Interstitial lung disease (ILD) is the most common lung manifestation of RA and the 2nd leading cause of death in RA patients.1,2 The purpose…
Abstract Number: 2717 • 2019 ACR/ARP Annual Meeting
Long-term Outcome of Juvenile-onset Psoriatic Arthritis
Devy Zisman¹, Tal Gazitt ², Amir Haddad ², Idit Lavi ², Snezana Barac ³, Vinod Chandran ⁴, Jan Dutz ⁵, Lihi Eder ⁶, James T Elder ⁷, Richard Hayday ⁸, Proton Rahman ⁹, Christopher Ritchlin ¹⁰, Sherry Rohekar ¹¹, Cheryl F. Rosen ¹² and Dafna Gladman ¹³, ¹Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, ²Carmel Hospital, Haifa, Israel, ³Winnipeg Clinic, Winnipeg, MB, Canada, ⁴Department of Medicine, University of Toronto,Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of British Columbia, Vancuver, BC, Canada, ⁶Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ⁷University of Michigan Medical School,, Ann Arbor, MI, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Memorial University, Newfoundland, NL, Canada, ¹⁰Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ¹¹Western University, London, ON, Canada, ¹²Division of Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: There is no consensus in the literature with regard to the features and long-term prognosis of psoriatic arthritis (PsA) starting in childhood (jPsA). We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].